It's nonsense because FUDsters want to focus on ancillary indications that are tertiary to obtaining drug approvals. As clearly stated by Missling, the primary and secondary focus for approvals are Rett and AD, respectively. The other indications can wait.
Anavex delivered never-before-seen AD P3 results, where patients functionally IMPROVED... and the avg decline was slowed by 45%, which included patients with gene variants. Anavex further PR'd strong efficacy results in Cog and CDR-SB with p<.025, each... along with significant biomarkers to validate the AA pathway.
But FUDsters want to ignore or deny all the positive data and twist it into a fake narrative.
The FUDsters are well known.
Missling is working the plan!
News 
Market Data 
Discover 
AI
